home / stock / blu / blu news

BLU News and Press, BELLUS Health Inc. From 05/28/20

Stock Information
Company Name: BELLUS Health Inc.
Stock Symbol: BLU
Market: NYSE
Website: bellushealth.com
Menu
BLU BLU Quote BLU Short BLU News BLU Articles BLU Message Board
Get BLU Alerts

News, Short Squeeze, Breakout and More Instantly...
BLU - BELLUS Health to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto B...
BLU - BELLUS Health EPS misses by $0.03

BELLUS Health (NASDAQ: BLU ): Q1 GAAP EPS of -$0.18 misses by $0.03 . More news on: BELLUS Health Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BLU - BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial a...

BLU - BELLUS Health (BLU) Investor Presentation - Slideshow

The following slide deck was published by BELLUS Health Inc. in conjunction with this Read more ...

BLU - BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a virtual Key Opinion...

BLU - BELLUS Health to Present at the BofA Securities Virtual Health Care Conference

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto B...

BLU - BELLUS Health Announces Change to Annual and Special Shareholder Meeting Format

Meeting to be held by webcast as a result of public health measures in response to the COVID-19 pandemic BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics f...
BLU - BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough

- Topline data on track for mid-year 2020 - BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitizati...

BLU - BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

- BELLUS now owns 100% of BLU-5937 and related P2X3 antagonist intellectual property with no future payments due - - 4.77 million BELLUS Health common shares issued in consideration - BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health...

BLU - Selloff creating bargains in healthcare - Baird

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
Previous 10 Next 10